Collegium Pharmaceutical, Inc. (COLL) News
Filter COLL News Items
COLL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
COLL News Highlights
- For COLL, its 30 day story count is now at 3.
- Over the past 9 days, the trend for COLL's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest COLL News From Around the Web
Below are the latest news stories about COLLEGIUM PHARMACEUTICAL INC that investors may wish to consider to help them evaluate COLL as an investment opportunity.
Collegium Pharmaceutical Inc CEO Joseph Ciaffoni Sells Company SharesOn December 21, 2023, Joseph Ciaffoni, President and CEO of Collegium Pharmaceutical Inc (NASDAQ:COLL), executed a sale of 4,357 shares of the company. |
Collegium Pharmaceutical Inc CEO Joseph Ciaffoni Sells 68,768 SharesJoseph Ciaffoni, the President and CEO of Collegium Pharmaceutical Inc (NASDAQ:COLL), sold 68,768 shares of the company on December 20, 2023, according to a recent SEC filing. |
Collegium Pharmaceutical (NASDAQ:COLL) ascends 8.3% this week, taking five-year gains to 77%The main point of investing for the long term is to make money. Better yet, you'd like to see the share price move up... |
Insider Sell: EVP and General Counsel Shirley Kuhlmann Sells 25,600 Shares of Collegium ...Shirley Kuhlmann, the Executive Vice President and General Counsel of Collegium Pharmaceutical Inc, has recently sold 25,600 shares of the company's stock. |
Appeals Court Upholds PTAB’s Finding of Invalidity of Purdue’s 961 PatentSTOUGHTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that the U.S. Court of Appeals for the Federal Circuit has upheld the judgment of the Patent Trial and Appeal Board (PTAB) in its final decision that Purdue’s ‘961 patent, which Purdue has claimed is infringed by Xtampza® ER, is invalid. The Federal Circuit’s decision affirming the invalidity of Purdue’s ‘961 patent confirms b |
12 Cheap NASDAQ Stocks To BuyIn this piece, we will take a look at the 12 cheap NASDAQ stocks to buy. To skip our overview of one of the world’s largest stock exchanges and some recent financial news, read 5 Cheap NASDAQ Stocks To Buy. Stocks markets have been taking a hammering over the past couple of years amid a […] |
Collegium Announces $25 Million Accelerated Share Repurchase ProgramSTOUGHTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $25 million of the Company’s common stock. Collegium will execute the ASR as part of the $100 million share repurchase program authorized |
Should You Be Worried About Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) 5.0% Return On Equity?One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will... |
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q3 2023 Earnings Call TranscriptCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Q3 2023 Earnings Call Transcript November 7, 2023 Collegium Pharmaceutical, Inc. misses on earnings expectations. Reported EPS is $0.53 EPS, expectations were $1.24. Operator: Greetings, and welcome to Collegium Pharmaceuticals Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow […] |
Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q3 EarningsWhile the top- and bottom-line numbers for Collegium Pharmaceutical (COLL) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |